Haleon plc (LSE:HLN) published its 2026 Q3 Trading Statement on 29 October 2026 and, minutes later, announced the start of a share buyback of up to £500 million running to February 2027. The consumer health group's twin updates put the FTSE 100 constituent in focus across the UK stock market on Thursday.

Haleon's 29 October announcements

Haleon released two regulatory announcements on the London Stock Exchange this morning. At 07:00 it issued its "2026 Q3 Trading Statement" covering the third quarter of the year ending 31 December 2026. At 07:05 it followed with a separate announcement confirming the commencement of a share buyback programme of up to £500 million.

The trading statement was released as a PDF attachment to the announcement, which could not be accessed for this article. As a result, the third-quarter revenue, organic growth and guidance figures are not reported here. The announcement confirms that Chief Executive Officer Brian McNamara and Chief Financial Officer Dawn Allen were scheduled to host a short presentation followed by a question-and-answer session at 9:00am GMT, with a webcast to be made available later on Haleon's investor website.

Details of the £500m share buyback

According to the buyback announcement, Haleon has entered into an irrevocable agreement with Citigroup Global Markets Limited (Citi) to carry out purchases of up to £500 million in aggregate. The programme will end no later than 19 February 2027, and Citi will make its trading decisions independently of the company, including during closed periods.

Purchases may be made on the London Stock Exchange, CBOE Europe and/or Aquis. The maximum number of shares that can be bought is 805,110,900, the unused balance of the authority granted at the annual general meeting held on 29 April 2026. The stated purpose is "to reduce the Company's share capital" and to meet employee share plan obligations. About 80% of the shares repurchased will be cancelled, with the remainder held in treasury to satisfy employee share plans in 2027 and 2028.

Background: Haleon's half-year position

For context, Haleon's 2026 half-year results, published on 30 July 2026, showed revenue of £5,602 million for the six months to 30 June, up 2.2%, with organic revenue growth of 2.6% and 3.1% organic growth in the second quarter. At that stage, the company kept its full-year 2026 guidance unchanged, stating "Organic revenue growth of 3%-5%" and "High-single digit adjusted operating profit growth at constant currency".

The half-year release also said Haleon (LSE:HLN) had allocated £500 million to share buybacks for 2026 and had completed £457 million of that by the half-year point. Today's announcement covers a new programme of up to £500 million running into 2027.

Risks investors may consider

Because the trading statement figures could not be verified here, readers should consult the full Q3 document for any change to guidance. Under the buyback, Citi controls timing independently, so the pace of purchases may vary with market conditions. More broadly, consumer health demand, currency movements and competition across its product categories can influence results for FTSE 100 consumer stocks such as Haleon.

What investors may watch next

Market participants may look to the full Q3 trading statement and webcast for revenue trends and any comment on full-year guidance. Regular transaction-in-own-shares announcements will show how quickly the £500 million programme progresses ahead of its 19 February 2027 end date. Haleon's full-year 2026 results will be the next major reporting milestone.

Haleon's update in the wider UK market

Haleon's morning combined a quarterly trading update with a fresh capital return programme, reinforcing its place among closely watched LSE stocks. For investors following UK shares, the detail inside the Q3 statement, together with the buyback's execution, will shape how this update is assessed.